Epidemiological evidence: IgE, allergies, and hematopoietic malignancies

Cancer and IgE: Introducing the Concept of AllergoOncology

Volumn , Issue , 2010, Pages 79-136

  Martínez Maza, Otoniel ^b   Moreno, Alan Duane ^a   Cozen, Wendy ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951536843     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-60761-451-7_5     Document Type: Chapter

References (141)

1. Eriksson N, Holmen A, Hogstedt B, Mikoczy Z, Hagmar L (1995) A prospective study of cancer incidence in a cohort examined for allergy. Allergy 50: 718-722
2. Lindelof B, Granath F, Tengvall-LinderM, Ekbom A (2005) Allergy and cancer. Allergy 60: 1116-1120
3. Lochmann O, Benes J, Vymola F, Pokorny J (1978) Observation of antibody activity against antibiotics in patients with atopic disease. J Hyg EpidemiolMicrobiol Immunol 22: 344-353
4. Ellison-Loschmann L, Benavente Y, Douwes J, Buendia E, Font R, Alvaro T, Kogevinas M, De Sanjose S (2007) Immunoglobulin E levels and risk of lymphoma in a case-control study in Spain. Cancer Epidemiol Biomarkers Prev 16: 1492-1498
5. Holly E, Chitra L (1997) Non-Hodgkin's lymphoma in HIV-positive and HIV-negative homosexual men in the San Francisco Bay area: Allergies, prior medication use, and sexual practices. J AIDS 15: 211-222
6. Groves FD, Linet MS, Devesa SS (1995) Patterns of occurrence of the leukaemias. Eur J Cancer 31A: 941-949
7. Jourdan-Da Silva N, Perel Y, Mechinaud F, Plouvier E, Gandemer V, Lutz P, Vannier J, Lamagnere J, Margueritte G, Boutard P, Robert A, Armari C, Munzer M, Millot F, De Lumley L, Berthou C, Rialland X, Pautard B, Hemon D, Clavel J (2004) Infections diseases in the first year of life, perinatal characteristics and childhood acute leukemia. Br J Cancer 90: 139-145
8. Rosenbaum P, Buck G, Brecher M (2005) Allergy and infectious disease histories and the risk of childhood acute lymphoblastic leukaemia. Paediatric Perinatal Epidemiol 19: 152-164
9. Schuz J, Morgan G, Bohler E, Kaatsch P, Michaelis J (2003) Atopic disease and childhood acute lymphoblastic leukemia. Int J Cancer 105: 255-260
10. WenW, Shu X, LinetM, Neglia J, Potter J, TriggM, Robison L (2000) Allergic disorders and the risk of childhood acute lymphoblastic leukemia (United States). Cancer Causes Contr 11: 303-307
11. Soderberg K, Jonsson F, Winqvist O, Hagmar L, FeychtingM(2006) Autoimmune diseases, asthma and risk of haematological malignancies: A nationwide case-control study in Sweden. Eur J Cancer 42: 3028-3033
12. Hughes A, Lightfoot T, Simpson J, Ansell P, McKinney P, Kinsey S, Mitchell C, Eden T, Greaves M, Roman E, United Kingdom Childhood Cancer Study Investigators (2007) Allergy and risk of childhood leukemia: Results from the UKCCS. Int J Cancer 121: 819-824
13. Spector L, Groves F, DeStefano F, Liff J, KleinM, Mullooly J, Black S, Shinefield H, Ward J, Marcy M, Vaccine Safety Datalink Project (2004) Medically recorded allergies and the risk of childhood acute lymphoblastic leukemia. Eur J Cancer 40: 579-584
14. Cooper G, Kamel F, Sandler D, Davey F, Bloomfield C (1996) Risk of adult acute leukemia in relation to prior immune-related conditions. Cancer Epidemiol Biomarkers Prev 5: 867-872
15. Severson R, Davis S, Thomas D, Stevens E, Heuser L, Sever L (1989) Acute myelocytic leukemia and prior allergies. J Clin Epidemiol 42: 995-1001
16. Vineis P, Crosignani P, Sacerdote C, Fontana A, Masala G, Miligi L, Nanni O, Ramazzotti V, Rodella S, Stagnaro E, Tumino R, Viganò C, Vindigni C, Costantini AS (2000) Haematopoietic cancer and medical history: A multicentre case control study. J Epidemiol Community Health 54: 4331-4436
17. Doody M, LinetM, Glass A, Friedman GD, Pottern LM, Boice JD Jr, Fraumeni JF Jr. (1992) Leukemia, lymphoma and multiple myeloma following selected medical conditions. Cancer Causes Contr 3: 449-456
18. Jaffe E, Harris N, Stein H, Vardiman J (2001) Pathology & genetics of tumours of haematopoietic and lymphoid tissues. In: Kleihues P, Sobin L (eds) World Health Organization Classification of Tumours. International Agency for Research on Cancer (IARC) Press, Lyon, France
19. Becker N, De Sanjose S, Nieters A, Maynadie M, Foretova L, Cocco P, Staines A, Alvaro T, Vornanen M, Brennan P, Boffetta P (2007) Birth order, allergies and lymphoma risk: Results of the European collaborative reserach project Epilymph. Leuk Res 31: 1365-1372
20. Melbye M, Smedby K, Lehtinen T, Rostgaard K, Glimelius B, Munksgaard L, Schöllkopf C, Sundström C, Chang ET, Koskela P, Adami H-O, Hjalgrim H (2007) Atopy and risk of non-Hodgkin lymphoma. JNCI 99: 158-166
21. Zhang Y, Holdford T, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut, United States women. Cancer Causes Contr 15: 419-428
22. Soderberg K, Hagmar K, Schwartzbaum J, Feychting M (2004) Allergic conditions and risk of hematopoietic malignancies in adults: A cohort study. BMC Public Health 4: 51-57
23. Morton L, Wang S, Cozen W, Linet M, Chatterjee N, Davis S, Severson R, Colt J, Vasef M, Rothman N, BLair A, Bernstein L, Cross A, De Roos A, Engels E, Hein D, Hill D, Keleman L, Lim U, Lynch C, Schenk M, Wacholder S, Ward M, Hoar Zahm S, Chanoock S, Cerhan J, Hartge P (2008) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 112: 5150-5160
24. Morton L, Wang S, SS D, Hartge P, Weisenburger D, Linet M (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107: 265-276
25. Bernstein L, Ross R (1992) Prior medication use and health history as risk factors for non- Hodgkin's lymphoma: Preliminary results from a case-control study in Los Angeles County. Cancer Res 52: 5510s-5515s
26. Briggs N, Levine R, Brann E (2002) Allergies and risk of non-Hodgkin's lymphoma by subtype. Cancer Epidemiol Biomarkers Prev 11: 401-407
27. Cozen W, Cerhan J, Martinez-Maza O, Ward M, Linet M, Colt J, Davis S, Severson R, Hartge P, Bernstein L (2007) The effect of atopy, childhood crowding and other immune-related factors on non-Hodgkin lymphoma risk. Cancer Causes Contr 18: 821-831
28. Fabbro-Peray P, Daures J-P, Rossi J-F (2001) Environmental risk factors for non-Hodgkin's lymphoma: A population-based case-control study in Languedoc-Rousillon, France. Cancer Causes Contr 12: 201-212
29. Grulich A, Vajdic C, Kaldor J, Hughes AM, Kricker A, Fritschi L, Turner JJ, Milliken S, Benke G, Armstrong BK (2005) Birth order, atopy, and risk of non-Hodgkin lymphoma. JNCI 97: 587-594
30. Holly E, Lele C, Bracci P, McGrath MS (1999) Case-control study of non-Hodgkin's lymphoma among women and heterosexual men in the San Francisco Bay area, California. Am J Epidemiol 150: 375-389
31. Kallen B, Gunnarskog J, Conradson T (1993) Cancer risk in asthmatic subjects selected from hospital discharge registry. Eur Resp J 6: 694-697
32. Turner M, Chen Y, Krewski D, Ghadirian P, Thun M, Calle E (2005) Cancer mortality among US men and women and asthma and hay fever. Am J Epidemiol 162: 212-221
33. Vesterinen E, Pukkala E, Timonen T, Aromaa A (1993) Cancer incidence among 78, 000 asthmatic patients. Int J Cancer 22: 976-982
34. Bracci P, Dalvi T, Holly E (2006) Residential history, family characteristics and non- Hodgkin's lymphoma, a population-based case-control study in the San Francisco Bay are. . Cancer Epidemiol Biomarkers Prev 15: 1287-1294
35. Holly E, Bracci P (2003) Population-based study of non-Hodgkin lymphoma, histology and medical history among human immunodeficiency virus-negative participants in San Francisco. Am J Epidemiol 158: 316-327
36. Whittemore A, Holly E, Lee I-M, Abel E, Adams R, Nickoloff B, Bley L, Peters J, Gibney C (1989) Mycosis fungoides in relation to environmental exposures and immune response: A case-control study. J Natl Cancer Inst 81: 1560-1567
37. Vajdic CM, Falster MO, De Sanjose S, Martínez-Maza O, Becker N, Bracci PM, Melbye M, Smedby KE, Engels EA, Turner J, Vineis P, Costantini AS, Holly EA, Kane E, Spinelli JJ, La Vecchia C, Zheng T, Chiu BC, Maso LD, Cocco P, Maynadié M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Cozen W, Grulich AE (2009) Atopic Disease and Risk of Non-Hodgkin Lymphoma: An InterLymph Pooled Analysis. Cancer Res 69: 6482-6489
38. Jarrett R (2006) Viruses and lymphoma/leukemia. J Pathol 208: 176-186
39. Cozen W, Katz J, Mack T (1992) Hodgkin's disease varies by cell type in Los Angeles. Cancer Epidemiol Biomarkers Preven 1: 261-268
40. Glaser S, Gulley M, Clarke C, Keegan T, Chang E, Shema S, Craig F, Diguiseppe J, Dorfman R, Mann R, Anton-Culver H, Ambinder R (2008) Racial/ethnic variation in EBV-positive classical Hodgkin lymphoma in California. Int J Cancer 123: 1499-1507
41. Skinnider B, Mak T (2002) The role of cytokines in classical Hodgkin lymphoma. Blood 99: 4283-4297
42. Romagnani S, Biagiotti R, Amadori A, Maggi E, Biti G, Bellesi G, Ricci M (1980) Hyperproduction of IgE and T-cell dysfunction in Hodgkin's disease. Int Arch Allergy Appl Immunol 63: 64-72
43. Amlot P, Green L (1978) Atopy and immunoglobulin E concentrations in Hodgkin's disease and other lymphomas. BMJ 1: 327-329
44. Samoszuk M, Ramzi E (1992) IgE, Reed-Sternberg cells, and eosinophilia in Hodgkin's Disease. Leuk Lymphoma 9: 315-319
45. Amlot P, Slaney J, Brown R (1983) Atopy-A favourable prognostic factor for survival in Hodgkin's disease. Br J Cancer 48: 209-215
46. Slivnik D, Ellis T, Nawrocki J, Risher R (1990) The impact of Hodgkin's disease on the immune system. Semin Oncol 17: 673-682
47. Chang E, Tongzhang Z, Weir E, Borowitz M, Mann R, Spiegelman D, Mueller N (2004a) Childhood social environment and Hodgkin's lymphoma: New findings from a populationbased case-control study. Cancer Epidemiol Biomarkers Prev 13: 1361-1370
48. Chang E, Zhang T, Lennette E, Weir E, Borowitz M, Mann R, Spiegelman D, Mueller N (2004b) Heterogeneity of risk factors and antibody profiles in Epstein-Barr virus genomepositive and -negative Hodgkin lymphoma. J Infect Dis 189: 2271-2281
49. Pahwa P, McDuffie H, Dosman J, Robson D, McLaughlin J, Spinelli J, Fincham S (2003) Exposure to animals and selected risk factors among Canadian farm residents with Hodgkin's Disease, multiple myeloma, or soft tissue sarcoma. J Occup Environ Med 45: 857-868
50. Kyle R, Thermeau T, Rajkumar S, Larson D, Plevak M, Offord J, Dispenzieri A, Katzmann J, Melton L, III (2006) Prevalence of monoclonal gammopathy of undetermined sigficance. N Eng J Med 354: 1362-1369
51. Cozen W, Hamilton AS, Zhao P, Salam MT, Deapen DK, Nathwani BN, Weiss LM, Mack TM (2009) A protective role for early childhood exposures and young adult Hodgkin lymphoma. Blood, epub doi: 10.1182/blood-2009-03-209601
52. Kyle R, Therneau T, Rajkumar S, Offord J, Larson D, Plevak M, Melton L, III (2002) A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Eng J Med 346: 564-569
53. Kairemo K, Lindberg M, Pyrtz M (1999) IgE myeloma: A case presentation and a review of the literature. Scan J Clin Lab Invest 59: 451-456
54. GebregziabherM, Bernstein L, Wang Y, CozenW(2006) Risk patterns of multiple myeloma in Los Angeles County, 1972-1999. Cancer Causes Control 17: 931-938
55. Cozen W, Gebregziabher M, Conti D, Van Den Berg D, Coetzee G, Wang S, Rothman N, Bernstein L, Hartge P, Morhbacher A, Coetzee S, Salam M, Wang W, Zadnick J, Ingles S (2006) Interleukin-6 related genotypes, body mass index and risk of multiple myeloma and plasmacytoma. . Cancer Epidemiol Biomarkers Preven 15: 2285-2291
56. Larsson S, Wolk A (2007) Body mass index and multiple myeloma: A meta-Analysis. Int J Cancer 121: 2512-2516
57. Alexander DD, Mink PJ, Adami HO, Cole P, Mandel JS, Oken MM, Trichopoulos D (2007) Multiple myeloma: A review of the epidemiologic literature. Int J Cancer 120(Suppl 12): 40-61, doi: 10.1002/ijc.22718
58. Bourguet C, Logue E (1993) Antigenic stimulation and multiple myeloma: A prospective study. Cancer 72: 2148-2154
59. Mills P, Beeson W, Fraser G, Phillips RL (1992) Allergy and cancer: Organ-site specific results from the Adventist Health Study. Am J Epidemiol 136: 287-295
60. Eriksson M (1993) Rheumatoid arthritis as a risk factor for multiple myeloma: A casecontrol study. Eur J Cancer 29A: 259-263
61. Koepsell T, Daling J, Weiss N, Taylor J, Olshan A, Lyon J, Swanson G, Child M (1987) Antigenic stimulation and the occurrence of multiple myeloma. Am J Epidemiol 126: 1051-1062
62. Landgren O, Zhang Y, Zham S, Inskip P, Zheng T, Baris D (2006) Risk of multiple myeloma following medication use and medical conditions: A case-control study in Connecticut women. Cancer Epidemiol Biomarkers Prev 15: 2342-2347
63. Lewis D, Pottern L, Brown L, Silverman D, Hayes R, Schoenberg J, Greenberg R, Swanson G, Schwartz A, Liff J, Hoover R (1994) Multiple myeloma among Blacks and Whites in the United States: The role of chronic antigenic stimulation Cancer Causes Contr 5: 529-539
64. Boffetta P, Stellman S, Garfinkel L (1989) A case-control study of multiple myeloma nested in the American Cancer Society prospective study. Int J Cancer 43: 554-559
65. Linet M, Harlow S, McLaughlin J, McCaffrey L (1989) A comparison of interview data and medical records for previous medical conditions and surgery. J Clin Epidemiol 42: 1207-1213
66. Burgess J, Walteres E, Byrnes G, Wharton C, Jenkins M, Abramson M, Hopper J, Dharmage S (2006) Who remembers whether they had asthma as children? J Asthma 43: 727-730
67. White LJ, Ozanne BW, Graber P, Aubry JP, Bonnefoy JY, Cushley W (1997) Inhibition of apoptosis in a human pre-B-cell line by CD23 is mediated via a novel receptor. Blood 90: 234-243
68. Chunsong H, Yuling H, Li W, Jie X, Gang Z, Qiuping Z, Qingping G, Kejian Z, Li Q, Chang AE, Youxin J, Jinquan T (2006) CXC chemokine ligand 13 and CC chemokine ligand 19 cooperatively render resistance to apoptosis in B cell lineage acute and chronic lymphocytic leukemia CD23+CD5+ B cells. J Immunol 177: 6713-6767
69. Fu SL, Pierre J, Smith-Norowitz TA, Hagler M, Bowne W, Pincus MR, Mueller CM, Zenilman ME, Bluth MH (2008) Immunoglobulin E antibodies from pancreatic cancer patients mediate antibody-dependent cell-mediated cytotoxicity against pancreatic cancer cells. Clin Exp Immunol 153: 401-409
70. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L, Riemer AB, Gould H (2008) AllergoOncology: The role of IgE-mediated allergy in cancer. Allergy 63: 1255-1266
71. Hartman ML, Lin SY, Jouvin MH, Kinet JP (2008) Role of the extracellular domain of Fc epsilon RI alpha in intracellular processing and surface expression of the high affinity receptor for IgE Fc epsilon RI. Mol Immunol 45: 2307-2311
72. Ozdemir O (2005) Immunosurveillance function of human mast cell?World J Gastroenterol 11: 7054-7056
73. Stingl G, Maurer D (1997) IgE-mediated allergen presentation via Fc epsilon RI on antigenpresenting cells. Int Arch Allergy Immunol 113: 24-29
74. Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ, Dombrowicz D, Balkwill FR, Gould HJ (2008) Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother 57: 247-263
75. Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F, Moore RJ, Dombrowicz DD, Balkwill FR, Gould HJ (2007) IgE-Antibody-dependent immunotherapy of solid tumors: Cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol 179: 2832-2843
76. Arase N, Arase H, Hirano S, Yokosuka T, Sakurai D, Saito T (2003) IgE-mediated activation of NK cells through Fc gamma RIII. J Immunol 170: 3054-3058
77. Gould HJ, Mackay GA, Karagiannis SN, O'Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR, Jr., Joseph M, Capron M, Gilbert M, Murphy GF, Korngold R (1999) Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol 29: 3527-3537
78. Sarfati M, Fournier S, Wu CY, Delespesse G (1992) Expression, regulation and function of human Fc epsilon RII (CD23) antigen. Immunol Res 11: 260-272
79. Bonnefoy JY, Lecoanet-Henchoz S, Gauchat JF, Graber P, Aubry JP, Jeannin P, Plater-Zyberk C (1997) Structure and functions of CD23. Int Rev Immunol 16: 113-128
80. Ochiai K, Wang B, Rieger A, Kilgus O, Maurer D, Fodinger D, Kinet JP, Stingl G, Tomioka H (1994) A review on Fc epsilon RI on human epidermal Langerhans cells. Int Arch Allergy Immunol 104(Suppl 1): 63-64
81. Wang B, Rieger A, Kilgus O, Ochiai K, Maurer D, Fodinger D, Kinet JP, Stingl G (1992) Epidermal Langerhans cells from normal human skin bind monomeric IgE via Fc epsilon RI. J Exp Med 175: 1353-1365
82. Prussin C, Metcalfe DD (2006) 5. IgE, mast cells, basophils, and eosinophils. J Allergy Clin Immunol 117: S450-S456
83. Kikutani H, Yokota A, Uchibayashi N, Yukawa K, Tanaka T, Sugiyama K, Barsumian EL, Suemura M, Kishimoto T (1989) Structure and function of Fc epsilon receptor II (Fc epsilon RII/CD23): A point of contact between the effector phase of allergy and B cell differentiation. Ciba Found Symp 147: 23-31; discussion 31-25
84. Rivera J, Olivera A (2008) A current understanding of Fc epsilon RI-dependent mast cell activation. Curr Allergy Asthma Rep 8: 14-20
85. Kolb JP, Abadie A, Paul-Eugene N, Capron M, Sarfati M, Dugas B, Delespesse G (1993) Ligation of CD23 triggers cyclic AMP generation in human B lymphocytes. J Immunol 150: 4798-4809
86. Paul-Eugene N, Kolb JP, Abadie A, Gordon J, Delespesse G, Sarfati M, Mencia-Huerta JM, Braquet P, Dugas B (1992) Ligation of CD23 triggers cAMP generation and release of inflammatory mediators in human monocytes. J Immunol 149: 3066-3071
87. Costain DJ, Guha AK, Liwski RS, Lee TD (2001) Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism. Cancer Immunol Immunother 50: 293-299
88. Strik MC, De Koning PJ, Kleijmeer MJ, Bladergroen BA, Wolbink AM, Griffith JM, Wouters D, Fukuoka Y, Schwartz LB, Hack CE, Van Ham SM, Kummer JA (2007) Human mast cells produce and release the cytotoxic lymphocyte associated protease granzyme B upon activation. Mol Immunol 44: 3462-3472
89. Strunk RC, Bloomberg GR (2006) Omalizumab for asthma. N Engl J Med 354: 2689-2695
90. Matta GM, Battaglio S, Dibello C, Napoli P, Baldi C, Ciccone G, Coscia M, Boccadoro M, Massaia M (2007) Polyclonal immunoglobulin E levels are correlated with hemoglobin values and overall survival in patients with multiple myeloma. Clin Cancer Res 13: 5348-5354
91. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjose S, Chiu BC, Dal Maso L, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: A pooled analysis within the InterLymph Consortium. Blood 111: 4029-4038
92. Gordon J (1992) CD23 and B cell activation. Clin Exp Allergy 22: 199-204
93. Yawetz S, Cumberland WG, Van Der Meyden M, Martinez-Maza O (1995) Elevated serum levels of soluble CD23 (sCD23) precede the appearance of acquired immunodeficiency syndrome-Associated non-Hodgkin's lymphoma. Blood 85: 1843-1849
94. Schroeder JR, Saah AJ, Ambinder RF, Martinez-Maza O, Crabb Breen E, Variakojis D, Margolick JB, Jacobson LP, Rowe DT, Hoover DR (1999) Serum sCD23 level in patients with AIDS-related non-Hodgkin's lymphoma is associated with absence of Epstein-Barr virus in tumor tissue. Clin Immunol 93: 239-244
95. Schroeder JR, Saah AJ, Hoover DR, Margolick JB, Ambinder RF, Martinez-Maza O, Breen EC, Jacobson LP, Variakojis D, Rowe DT, Armenian HK (1999) Serum soluble CD23 level correlates with subsequent development of AIDS-related non-Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 8: 979-984
96. Hannig H, Buske C, Matz-Rensing K, Hunsmann G, Hiddemann W, Bodemer W (1998) Elevated serum level of soluble CD23 precedes development of B-non-Hodgkin's lymphoma in SIV-infected Rhesus monkeys. Int J Cancer 77: 734-740
97. Kawabe T, Takami M, Hosoda M, Maeda Y, Sato S, Mayumi M, Mikawa H, Arai K, Yodoi J (1988) Regulation of Fc epsilon R2/CD23 gene expression by cytokines and specific ligands (IgE and anti-Fc epsilon R2 monoclonal antibody). Variable regulation depending on the cell types. J Immunol 141: 1376-1382
98. Ford JW, Kilmon MA, Haas KM, Shelburne AE, Chan-Li Y, Conrad DH (2006) In vivo murine CD23 destabilization enhances CD23 shedding and IgE synthesis. Cell Immunol 243: 107-117
99. Fournier S, Delespesse G, Rubio M, Biron G, Sarfati M (1992) CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 89: 1312-1321
100. Conrad DH, Ford JW, Sturgill JL, Gibb DR (2007) CD23: An overlooked regulator of allergic disease. Curr Allergy Asthma Rep 7: 331-337
101. Yamada T, Zhu D, Zhang K, Saxon A (2003) Inhibition of interleukin-4-induced class switch recombination by a human immunoglobulin Fc gamma-Fc epsilon chimeric protein. J Biol Chem 278: 32818-32824
102. Oettgen HC, Geha RS (2001) IgE regulation and roles in asthma pathogenesis. J Allergy Clin Immunol 107: 429-440
103. Smedby KE, Hjalgrim H, Askling J, Chang ET, Gregersen H, Porwit-MacDonald A, Sundstrom C, Akerman M, Melbye M, Glimelius B, Adami HO (2006) Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. J Natl Cancer Inst 98: 51-60
104. Romagnani S (2008) Human Th17 cells. Arthritis Res Ther 10: 206
105. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S (2007) Phenotypic and functional features of human Th17 cells. J Exp Med 204: 1849-1861
106. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S (2008) The phenotype of human Th17 cells and their precursors, the cytokines that mediate their differentiation and the role of Th17 cells in inflammation. Int Immunol 20: 1361-1368
107. Korn T, Oukka M, Kuchroo V, Bettelli E (2007) Th17 cells: Effector T cells with inflammatory properties. Semin Immunol 19: 362-371
108. Katsifis GE, Moutsopoulos NM, Wahl SM (2007) T lymphocytes in Sjogren's syndrome: Contributors to and regulators of pathophysiology. Clin Rev Allergy Immunol 32: 252-264
109. Stockinger B, Veldhoen M (2007) Differentiation and function of Th17 T cells. Curr Opin Immunol 19: 281-286
110. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM (2006) Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677-688
111. Ouyang W, Kolls JK, Zheng Y (2008) The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 28: 454-467
112. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T (1998) Creactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 31: 351-357
113. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, Jaffe ES, Karp JE, Broder S, Yarchoan R (1993) Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. J Clin Oncol 11: 1099-1107
114. Breen EC, Van Der Meijden M, Cumberland W, Kishimoto T, Detels R, Martinez-Maza O (1999) The development of AIDS-Associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin-6. Clin Immunol 92: 293-299
115. el-Far M, Fouda M, Yahya R, el-Baz H (2004) Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin's lymphoma. J Physiol Biochem 60: 253-258
116. Pedersen LM, Klausen TW, Davidsen UH, Johnsen HE (2005) Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non- Hodgkin's lymphoma. Ann Hematol 84: 510-516
117. Niitsu N, Okamato M, Nakamine H, Yoshino T, Tamaru J, Nakamura S, Higashihara M, HiranoM(2002) Simultaneous elevation of the serum concentrations of vascular endothelial growth factor and interleukin-6 as independent predictors of prognosis in aggressive non- Hodgkin's lymphoma. Eur J Haematol 68: 91-100
118. Fayad L, Cabanillas F, TalpazM, McLaughlin P, Kurzrock R (1998) High serum interleukin- 6 levels correlate with a shorter failure-free survival in indolent lymphoma. Leuk Lymphoma 30: 563-571
119. Kato H, Kinoshita T, Suzuki S, Nagasaka T, Hatano S, Murate T, Saito H, Hotta T (1998) Production and effects of interleukin-6 and other cytokines in patients with non-Hodgkin's lymphoma. Leuk Lymphoma 29: 71-79
120. Voorzanger N, Touitou R, Garcia E, Delecluse HJ, Rousset F, Joab I, Favrot MC, Blay JY (1996) Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors. Cancer Res 56: 5499-5505
121. Kato H, Kinoshita T, Suzuki S, Nagasaka T, Murate T, Saito H, Hotta T (1996) Elevated serum interleukin-6 (IL-6) is derived from neoplastic lymphoid cells in patients with B-cell non-Hodgkin's lymphoma: Correlation with extent of IL-6 expression and serum concentration. Br J Haematol 92: 1014-1021
122. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T (1989) IgG1 plasmacytosis in interleukin-6 transgenic mice. Proc Natl Acad Sci USA 86: 7547-7551
123. Wang SS, Cozen W, Cerhan JR, Colt JS, Morton LM, Engels EA, Davis S, Severson RK, Rothman N, Chanock SJ, Hartge P (2007) Immune mechanisms in non-Hodgkin lymphoma: Joint effects of the TNF G308A and IL10 T3575A polymorphisms with non-Hodgkin lymphoma risk factors. Cancer Res 67: 5042-5054
124. Purdue MP, Lan Q, Kricker A, Grulich AE, Vajdic CM, Turner J, Whitby D, Chanock S, Rothman N, Armstrong BK (2007) Polymorphisms in immune function genes and risk of non-Hodgkin lymphoma: Findings from the New South Wales non-Hodgkin Lymphoma Study. Carcinogenesis 28: 704-712
125. Wang SS, Cerhan JR, Hartge P, Davis S, Cozen W, Severson RK, Chatterjee N, Yeager M, Chanock SJ, Rothman N (2006) Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma. Cancer Res 66: 9771-9780
126. O. Martínez-Maza et al. 126. Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ, Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A, Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR, Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS, Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y, Severson RK, Yeager M, Chanock S, Nieters A (2006) Genetic variation in TNF and IL10 and risk of non-Hodgkin lymphoma: A report from the InterLymph Consortium. Lancet Oncol 7: 27-38
127. Sappino AP, Seelentag W, Pelte MF, Alberto P, Vassalli P (1990) Tumor necrosis factor/cachectin and lymphotoxin gene expression in lymph nodes from lymphoma patients. Blood 75: 958-962
128. Macia J, Gomez X, Esquerda A, Perez B, Callao V, Marzo C (1996) Value of the determination of TNF-Alpha in the plasma of patients with non-Hodgkins lymphoma. Leuk Lymphoma 20: 481-486
129. Warzocha K, Salles G, Bienvenu J, Bastion Y, Dumontet C, Renard N, Neidhardt-Berard EM, Coiffier B (1997) Tumor necrosis factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol 15: 499-508
130. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G (1998) Genetic polymorphisms in the tumor necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood 91: 3574-3581
131. Lissoni P, Bolis S, Mandala M, Viviani S, Pogliani E, Barni S (1999) Blood concentrations of tumor necrosis factor-Alpha in malignant lymphomas and their decrease as a predictor of disease control in response to low-dose subcutaneous immunotherapy with interleukin-2. Int J Biol Markers 14: 167-171
132. Seidemann K, Zimmermann M, Book M, Meyer U, Burkhardt B, Welte K, Reiter A, Stanulla M (2005) Tumor necrosis factor and lymphotoxin alfa genetic polymorphisms and outcome in pediatric patients with non-Hodgkin's lymphoma: Results from Berlin- Frankfurt-Munster Trial NHL-BFM 95. J Clin Oncol 23: 8414-8421
133. Spink CF, Keen LJ, Mensah FK, Law GR, Bidwell JL, Morgan GJ (2006) Association between non-Hodgkin lymphoma and haplotypes in the TNF region. Br J Haematol 133: 293-300
134. Bel Hadj Jrad B, Chatti A, Laatiri A, Ahmed SB, Romdhane A, Ajimi S, Chouchane L (2007) Tumor necrosis factor promoter gene polymorphism associated with increased susceptibility to non-Hodgkin's lymphomas. Eur J Haematol 78: 117-122
135. Nowak J, Kalinka-Warzocha E, Juszczynski P, Bilinski P, Mika-Witkowska R, Zajko M, Bienvenu J, Coiffier B, Salles G, Warzocha K (2007) Association of human leukocyte antigen ancestral haplotype 8.1 with adverse outcome of non-Hodgkin's lymphoma. Genes, Chromosomes & Cancer 46: 500-507
136. Skibola CF, Curry JD, Nieters A (2007) Genetic susceptibility to lymphoma. Haematologica 92: 960-969
137. Suematsu S, Hibi M, Sugita T, Saito M, Murakami M, Matsusaka T, Matsuda T, Hirano T, Taga T, Kishimoto T (1990) Interleukin 6 (IL-6) and its receptor (IL-6R) in myeloma/plasmacytoma. Curr Top Microbiol Immunol 166: 13-22
138. Ma CS, Chew GY, Simpson N, Priyadarshi A, Wong M, Grimbacher B, Fulcher DA, Tangye SG, Cook MC (2008) Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J Exp Med 205: 1551-1557
139. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, Kanno Y, Spalding C, Elloumi HZ, Paulson ML, Davis J, Hsu A, Asher AI, O'Shea J, Holland SM, Paul WE, Douek DC (2008) Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 452: 773-776
140. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, Fossiez F, Ryffel B, Schnyder B (2006) Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med 203: 2715-2725
141. Wang YH, Liu YJ (2008) The IL-17 cytokine family and their role in allergic inflammation. Curr Opin Immunol 20: 697-702